BioSpace News Archive

Cytek Biosciences, Inc., announced the company will be participating in the upcoming 31st Annual Credit Suisse Healthcare Conference in Rancho Palos Verdes, CA.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that an oral presentation highlighting clinical data from the Phase 3 INVIGORATE allergen chamber trial of reproxalap in allergic conjunctivitis will be presented at the American Academy of Optometry 2022 Annual Meeting, taking place in San Diego October 26-29, 2022.

Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium.

Pieris Pharmaceuticals, Inc. today announced that it will host a third quarter 2022 investor call on Wednesday, November 2, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.

Allogene Therapeutics, Inc. today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022, after the close of the market.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report third quarter 2022 financial results after the market close on Monday, November 7, 2022.

Acer Therapeutics Inc. (Nasdaq: ACER) today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Acer’s patent application No. 16/930,208, exclusively licensed from Assistance Publique—Hôpitaux de Paris, for claims related to certain methods of treating vascular Ehlers-Danlos syndrome (vEDS) with celiprolol.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, November 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2022 financial results.

Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the second quarter of fiscal year 2022 and provided other corporate updates.

TC BioPharm today announced the company has completed its scientific advisory board (SAB) to advance new therapeutic trials and establish strategic relationships within the cell therapy sector.